Tag: editing

MUMBAI, India, July 3, 2025 /PRNewswire/ -- Bound, India's leading creative education platform, announces the next edition of The Bound Publishing Course, a first-of-its-kind,...

VANCOUVER, BC, July 2, 2025 /PRNewswire/ -- MiniTool Software Limited has released a new version of its video conversion tool – MiniTool Video Converter 4.3. This...

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

HO CHI MINH CITY, July 1, 2025 /PRNewswire/ -- The Vietnam Career & Training Fair (VCTF) 2025, Vietnam's first professional recruitment and training event,...

FRANKFURT, Germany, June 30, 2025 /PRNewswire/ -- BleeqUp, an AI-powered outdoor sports technology brand, showcased its groundbreaking BleeqUp Ranger at Eurobike 2025. Hailed as...

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

"Comprehensive Review Highlights Market Growth, Innovation, and Investment Trends Driving the Future of Cell and Gene Therapy Tools, Biomanufacturing, and Gene Synthesis" BOSTON, June 20, 2025...

Including the launch of two Netflix Houses, TI's $60B semiconductor investment,Americans' favorite road trip snacks and the debut of Trump Mobile.  NEW YORK, June 20,...